0 10 Activation Activation NNP 11 13 of of IN 14 22 NF-kappa NF-kappa NNP 23 24 B B NNP 25 27 by by IN 28 39 interleukin interleukin NN 40 41 2 2 CD 42 44 in in IN 45 50 human human JJ 51 56 blood blood NN 57 66 monocytes monocyte NNS 66 67 . . . 69 71 We we PRP 72 78 report report VBP 79 83 here here RB 84 88 that that IN 89 100 interleukin interleukin NN 101 102 2 2 CD 103 104 ( ( ( 104 108 IL-2 il-2 NN 108 109 ) ) ) 110 114 acts act VBZ 115 117 on on IN 118 123 human human JJ 124 129 blood blood NN 130 139 monocytes monocyte NNS 140 142 by by IN 143 152 enhancing enhance VBG 153 160 binding binding NN 161 169 activity activity NN 170 172 of of IN 173 176 the the DT 177 190 transcription transcription NN 191 197 factor factor NN 198 206 NF-kappa NF-kappa NNP 207 208 B B NNP 209 211 to to TO 212 215 its its PRP$ 216 225 consensus consensus NN 226 234 sequence sequence NN 235 237 in in IN 238 241 the the DT 242 243 5 5 CD 243 244 ’ ' SYM 245 255 regulatory regulatory JJ 256 264 enhancer enhancer NN 265 271 region region NN 272 274 of of IN 275 278 the the DT 279 283 IL-2 il-2 NN 284 292 receptor receptor NN 293 298 alpha alpha NN 299 304 chain chain NN 305 306 ( ( ( 306 309 p55 p55 NN 309 310 ) ) ) 310 311 . . . 312 321 Similarly similarly RB 321 322 , , , 323 327 IL-2 IL-2 NNP 328 337 activates activate VBZ 338 346 NF-kappa NF-kappa NNP 347 348 B B NNP 349 351 in in IN 352 355 the the DT 356 361 human human JJ 362 371 monocytic monocytic JJ 372 376 cell cell NN 377 381 line line NN 382 383 U U NNP 384 387 937 937 CD 387 388 , , , 389 392 but but CC 393 396 not not RB 397 399 in in IN 400 407 resting rest VBG 408 413 human human JJ 414 421 T-cells t-cell NNS 421 422 . . . 423 427 This this DT 428 434 effect effect NN 435 437 is be VBZ 438 448 detectable detectable JJ 449 455 within within IN 456 458 15 15 CD 459 462 min min NN 463 466 and and CC 467 472 peaks peak VBZ 473 474 1 1 CD 475 476 h h NN 477 482 after after IN 483 491 exposure exposure NN 492 494 to to TO 495 499 IL-2 il-2 NN 499 500 . . . 501 509 Enhanced enhance VBN 510 518 NF-kappa NF-kappa NNP 519 520 B B NNP 521 528 binding binding NN 529 537 activity activity NN 538 540 is be VBZ 541 549 followed follow VBN 550 552 by by IN 553 563 functional functional JJ 564 574 activation activation NN 575 577 in in IN 578 582 that that DT 583 595 inducibility inducibility NN 596 598 of of IN 599 602 the the DT 603 607 IL-2 il-2 NN 608 616 receptor receptor NN 617 622 alpha alpha NN 623 628 chain chain NN 629 631 is be VBZ 632 640 mediated mediate VBN 641 643 by by IN 644 652 enhanced enhance VBN 653 661 NF-kappa NF-kappa NNP 662 663 B B NNP 664 671 binding binding NN 672 675 and and CC 676 680 that that IN 681 682 a a DT 683 695 heterologous heterologous JJ 696 704 promoter promoter NN 705 715 containing contain VBG 716 719 the the DT 720 728 NF-kappa NF-kappa NNP 729 730 B B NNP 731 740 consensus consensus NN 741 749 sequence sequence NN 750 751 ( ( ( 751 755 -291 -291 CD 756 758 to to TO 759 763 -245 -245 CD 763 764 ) ) ) 765 767 of of IN 768 771 the the DT 772 776 IL-2 il-2 NN 777 785 receptor receptor NN 786 791 alpha alpha NN 792 797 chain chain NN 798 802 gene gene NN 803 805 is be VBZ 806 815 activated activate VBN 815 816 . . . 817 819 In in IN 820 828 addition addition NN 828 829 , , , 830 834 IL-2 il-2 NN 835 837 is be VBZ 838 845 capable capable JJ 846 848 of of IN 849 859 increasing increase VBG 860 870 transcript transcript NN 871 877 levels level NNS 878 880 of of IN 881 884 the the DT 885 888 p50 p50 NN 889 893 gene gene NN 894 900 coding cod VBG 901 904 for for IN 905 908 the the DT 909 912 p50 p50 NN 913 920 subunit subunit NN 921 923 of of IN 924 927 the the DT 928 936 NF-kappa NF-kappa NNP 937 938 B B NNP 939 952 transcription transcription NN 953 959 factor factor NN 959 960 , , , 961 968 whereas whereas IN 969 973 mRNA mrna NN 974 980 levels level NNS 981 983 of of IN 984 987 the the DT 988 991 p65 p65 NN 992 1000 NF-kappa NF-kappa NNP 1001 1002 B B NNP 1003 1007 gene gene NN 1008 1016 remained remain VBD 1017 1026 unchanged unchanged JJ 1026 1027 . . .